A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization

Journal of Managed Care Pharmacy

Volumn 20, Issue 7, 2014, Pages 677-684

  Happe, Laura E ^a,b   Clark, Deanna ^c   Holliday, Edana ^d   Young, Tramaine ^d  

^a HUMANA INC   (United States)

^b PRESBYTERIAN COLLEGE   (United States)

^c St Francis Health System   (United States)

^d College School of Pharmacy ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG COST; DRUG FORMULARY; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MANAGED CARE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; SYSTEMATIC REVIEW; ECONOMICS; HEALTH INSURANCE; HEALTH SERVICE; ORGANIZATION AND MANAGEMENT; PUBLICATION; UTILIZATION; CLINICAL OUTCOME; PHARMACY;

FORMULARIES AS TOPIC; HEALTH SERVICES; HUMANS; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84903143339     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.7.677     Document Type: Article

References (107)

1. Centers for Medicare and Medicaid Services, Office of the Actuary, National Health Statistics Group; U.S. Dept of Commerce, Bureau of Economic Analysis; and U.S. Bureau of the Census. Table 1. National health expenditures; aggregate and per capita amounts, annual percent change and percent distribution: selected calendar years 1960-2012. Available at: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and- Reports/NationalHealthExpendData/Downloads/tables.pdf. Accessed May 6, 2014.
2. IMS Institute for Health Care Informatics. Declining medicine use and costs: for better or for worse. April 2012. Available at: http://www.imshealth. com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22 a/?vgnextoid=5b21ee0a8e631410VgnVCM10000076192ca2RCRD. Accessed June 4, 2014.
3. The Kaiser Family Foundation and Health Research & Educational Trust. Employer health benefits 2010: annual survey. September 2010. Available at: http://kaiserfamilyfoundation.files.wordpress.com/2013/04/8085.pdf. Accessed June 4, 2014.
4. Academy of Managed Care Pharmacy. Principles of a sound drug formulary system. October 2000. Available at: www.amcp.org/WorkArea/DownloadAsset.aspx?id=9280.
5. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.
6. Lu CY, Ross-Degnan D, Soumerai SB, Pearson SA. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature-2001-2007. BMC Health Serv Res. 2008;8:75.
7. Shoemaker SJ, Pozniak A, Subramanian R, Mauch D. Effect of 6 managed care pharmacy tools: a review of the literature. J Manag Care Pharm. 2010;16(6 Suppl):S3-S20. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8359.
8. Horn SD, Sharkey PD, Tracy DM, et al. Intended and unintended consequences of HMO cost-containment strategies: result from the Managed Care Outcomes Project. Am J Manag Care. 1996;2:253-64.
9. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-40.
10. Philipson TJ, Mozaffari E, Maclean JR. Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome. Am J Manag Care. 2010;16(4):290-97.
11. Patterson ME, Blalock SJ, Smith AJ, Murray MD. Associations between prescription copayment levels and beta-blocker medication adherence in commercially insured heart failure patients 50 years and older. Clin Ther. 2011;33(5):608-16.
12. Subramanian S. Impact of Medicaid copayments on patients with cancer: lessons for Medicaid expansion under health reform. Med Care. 2011;49(9):842-47.
13. Ovsag K, Hydery S, Mousa SA. Preferred drug lists: potential impact on healthcare economics. Vasc Health Risk Manag. 2008;4(2):403-13.
14. Gleason PP, Gunderson BW, Gericke KR. Are incentive-based formularies inversely associated with drug utilization in managed care? Ann Pharmacother. 2005;39(2):339-45.
15. Olson BM. Approaches to pharmacy benefit management and the impact of consumer cost sharing. Clin Ther. 2003;25(1):250-72.
16. EMD Serono. EMD Serono Specialty Digest, 9th edition: Managed care strategies for specialty pharmaceuticals. 2013. Available at: http://www. amcp.org/EMDSeronoSpecialtyDigest9th.pdf. Accessed May 21, 2014.
17. Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther. 1993;15(6):1121-32.
18. Louder AM, Joshi AV, Ball AT, Cappelleri JC, Deminski MC, Sanchez RJ. Impact of Celecoxib restrictions in medicare beneficiaries with arthritis. Am J Manag Care. 2011;17(7):503-12.
19. Mark TL, Gibson TM, McGuigan K, Chu BC. The effects of antidepressant step therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Psychiatry. 2010;167(10):1202-09.
20. Mark TL, Gibson TB, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. Am J Manag Care. 2009;15(2):123-31.
21. Panzer PE, Regan TS, Chiao E, Sarnes MW. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders. Am J Manag Care. 2005;11(12 Suppl):S370-S79.
22. Suehs BT, Louder A, Udall M, Cappelleri JC, Joshi AV, Patel NC. Impact of a pregabalin step therapy policy among Medicare Advantage beneficiaries. Pain Pract. 2013;May 23 [Epub ahead of print].
23. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health. 2006;9(2):77-89.
24. Udall M, Louder A, Suehs BT, Cappelleri JC, Joshi AV, Patel NC. Impact of a step-therapy protocol for pregabalin on healthcare utilization and expenditures in a commercial population. J Med Econ. 2013;16(6):784-92.
25. Williams SA, Buysman EK, Hulbert EM, Bergeson JG, Zhang B, Graham J. Hemoglobin A1c outcomes and health care resource use in type 2 diabetes mellitus patients treated with combination oral antidiabetic drugs through step therapy and loose-dose and fixed-dose combinations. Manag Care. 2012;21(7):40-48.
26. Balkrishnan R, Byerly WG, Camacho FT, Shrestha A, Anderson RT. Effect of prescription benefit changes on medical care utilization in a Medicare HMO population. Am J Manag Care. 2001;7(11):1093-100.
27. Barron J, Wahl P, Fisher M, Plauschiant C. Effect of prescription copayments on adherence and treatment failure with oral antidiabetic medications. PT. 2008;33(9):532-53.
28. Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin. 2010;26(8):1957-65.
29. Briesacher BA, Limcangco MR, Frech-Tamas F. New-user persistence with antihypertensives and prescription drug cost-sharing. J Clin Hyperten. 2007;9(11):831-36.
30. Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE. Effects of benefit design change across 5 disease states. Am J Manag Care. 2007;13(6 Pt 2):370-76.
31. Burke JP, Sander S, Shah H, Zarotsky V, Henk H. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. Curr Med Res Opin. 2010;26(5):1023-30.
32. Campbell JD, Allen-Ramey F, Sajjan SG, Maiese EM, Sullivan SD. Increasing pharmaceutical copayments: impact on asthma medication utilization and outcomes. Am J Manag Care. 2011;17(10):703-10.
33. Chernew M, Gibson TB. Cost sharing and HEDIS performance. Med Care Res Rev. 2008;65(6):713-28.
34. Chernew M, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. J Gen Intern Med. 2008;23(8):1131-36.
35. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-12.
36. Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-97.
37. Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy. 2006;26(8):1157-64.
38. Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010;29(11):1995-2001.
39. Colombi AM, Yu-Isenberg K, Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med. 2008;50(5):535-41.
40. Cooke CE, Lee HY, Tong YP, Haines ST. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26(1):231-38.
41. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient outof- pocket payments matter? Arthritis Rheum. 2008;59(10):1519-26.
42. Domino ME, Martin BC, Wiley-Exley E, et al. Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment. Health Serv Res. 2011;46(3):900-19.
43. Dor A, Lage MJ, Tarrants ML, Castelli-Haley J. Cost sharing, benefit design, and adherence: the case of multiple sclerosis. Adv Health Econ Health Serv Res. 2010;22:175-93.
44. Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation. 2009;119(3):390-97.
45. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-45.
46. Fairman KA, Motheral BR, Henderson RR. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs. Clin Ther. 2003;25(12):3147-61.
47. Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12(9):509-17.
48. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12(Spec No.):SP11-19.
49. Gibson T, Jiny Y, Kim E, et al. Cost sharing effects on adherence and persistence for second-generation antipsychotics in commercially insured patients. Manag Care. 2010;19(8):40-47.
50. Gilman BH, Kautter J. Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries. Health Serv Res. 2008;43(2):478-95.
51. Gilman BH, Kautter J. Consumer response to dual incentives under multitiered prescription drug formularies. Am J Manag Care. 2007;13(6 Pt 2):353-59.
52. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648-58. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8229.
53. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28.
54. Gu Q, Zeng F, Patel BV, Tripoli LC. Part D coverage gap and adherence to diabetes medications. Am J Manag Care. 2010;16(12):911-18.
55. Hartung DM, Carlson MJ, Kraemer DF, Haxby DG, Ketchum KL, Greenlick MR. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population. Med Care. 2008;46(6):565-72.
56. Huskamp HA, Deverka PA, Epstein AM, et al. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children. Arch Gen Psychiatry. 2005;62(4):435-41.
57. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care. 1997;35(11):1119-31.
58. Kessler RC, Cantrell CR, Berglund P, Sokol MC. The effects of copayments on medication adherence during the first two years of prescription drug treatment. J Occup Environ Med. 2007;49(6):597-609.
59. Kim YA, Rascati KL, Prasla K, Godley P, Goel N, Dunlop D. Retrospective evaluation of the impact of copayment increases for specialty medications on adherence and persistence in an integrated health maintenance organization system. Clin Ther. 2011;33(5):598-607.
60. Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care. 2005;11(10):621-28.
61. Lurk JT, DeJong DJ, Woods TM, Knell ME, Carroll CA. Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting. Am J Health Syst Pharm. 2004;61(3):267-72.
62. Maciejewski ML, Bryson CL, Perkins M, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manag Care. 2010;16(1):e20-34.
63. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002-08.
64. Motheral B, Fairman KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39(12):1293-304.
65. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534-42.
66. Pedan A, Varasteh L, Schneeweiss S. Analysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristics. J Manag Care Pharm. 2007;13(6):487-96. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=7639.
67. Pugh MJ, Starner CI, Amuan ME, et al. Exposure to potentially harmful drug-disease interactions in older community-dwelling veterans based on the Healthcare Effectiveness Data and Information Set quality measure: who is at risk? J Am Geriatr Soc. 2011;59(9):1673-78.
68. Schultz JS, O'Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care. 2005;11(5):306-12.
69. Sedjo RL, Cox ER. Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manag Care. 2008;14(12):813-18.
70. Shrank WH, Choudhry NK, Fischer MA, et al. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med. 2010;153(10):633-40.
71. Taira DA, Wong KS, Frech-Tamas F, Chung RS. Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care. Am J Manag Care. 2006;12(11):678-83.
72. Wiegand P, McCombs JS, Wang JJ. Factors of hyperlipidemia medication adherence in a nationwide health plan. Am J Manag Care. 2012;18(4):193-99.
73. Yang W, Kahler KH, Fellers T, et al. Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy. J Med Econ. 2011;14(3):267-78.
74. Ye X, Gross CR, Schommer J, Cline R, St Peter WL. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study. Clin Ther. 2007;29(12):2748-57.
75. Yoon J, Ettner SL. Cost-sharing and adherence to antihypertensives for low and high adherers. Am J Manag Care. 2009;15(11):833-40.
76. Zeber JE, Grazier KL, Valenstein M, Blow FC, Lantz PM. Effect of a medication copayment increase in veterans with schizophrenia. Am J Manag Care. 2007;13(6 Pt 2):335-46.
77. Zeng F, An JJ, Scully R, Barrington C, Patel BV, Nichol MB. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13(6):846-52.
78. Zhang D, Carlson AM, Gleason PP, et al. Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers. J Manag Care Pharm. 2007;13(8):664-76. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=7725.
79. Abouzaid S, Jutkowitz E, Foley KA, Pizzi LT, Kim E, Bates J. Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia. Popul Health Manag. 2010;13(5):247-54.
80. Adams AS, Zhang F, LeCates RF, et al. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Arch Intern Med. 2009;169(8):750-56.
81. Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. J Manag Care Pharm. 2010;16(1):15-22. Available at: http://www.amcp. org/WorkArea/DownloadAsset.aspx?id=8265.
82. Delate T, Mager DE, Sheth J, Motheral BR. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11(1):29-36.
83. Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications. Clin Ther. 2008;30(8):1524-39.
84. Gleason PP, Williams C, Hrdy S, Hartwig SC, Lassen D. Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program. Pharmacotherapy. 2005;25(7):924-34.
85. Hartung DM, Ketchum KL, Haxby DG. An evaluation of Oregon's evidence-based Practitioner-Managed Prescription Drug Plan. Health Aff (Millwood). 2006;25(5):1423-32.
86. Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Goldberg BW. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clin Ther. 2004;26(9):1518-32.
87. Law MR, Lu CY, Soumerai SB, et al. Impact of two Medicaid priorauthorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther. 2010;32(4):729-41.
88. Margolis JM, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care. 2010;16(6):447-56.
89. Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care. 2009;15(10):e95-102.
90. McCombs JS, Shi L, Stimmel GL, Croghan TW. A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clin Ther. 2002;24(11):1939-59.
91. Momani AA, Madhavan SS, Nau DP. Impact of NSAIDs prior authorization policy on patients' QoL. Ann Pharmacother. 2002;36(11):1686-91.
92. Simeone JC, Marcoux RM, Quilliam BJ. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program. J Manag Care Pharm. 2010;16(5):317-28. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=8347.
93. Siracuse MV, Vuchetich PJ. Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska. Health Serv Res. 2008;43(1 Pt 2):435-50.
94. Smalley WE, Griffin MR, Fought RL, Sullivan L, Ray WA. Effect of a prior-authorization requirement on the use of nonsteroidal antiinflammatory drugs by Medicaid patients. N Engl J Med. 1995;332(24):1612-17.
95. Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood). 2008;27(3):w185-95.
96. Starner CI, Fenrick B, Coleman J, Wickersham P, Gleason PP. Rosiglitazone prior authorization safety policy: a cohort study. J Manag Care Pharm. 2012;18(3):225-33. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=14970.
97. Walthour A, Seymour L, Tackett R, Perri M. Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents. Ann Pharmacother. 2010;44(5):809-18.
98. Zhang Y, Adams AS, Ross-Degnan D, Zhang F, Soumerai SB. Effects of prior authorization on medication discontinuation among Medicaid beneficiaries with bipolar disorder. Psychiatr Serv. 2009;60(4):520-27.
99. Johnson TJ, Stahl-Moncada S. Medicaid prescription formulary restrictions and arthritis treatment costs. Am J Public Health. 2008;98(7):1300-05.
100. Lichtenberg FR. The effect of access restrictions on the vintage of drugs used by Medicaid enrollees. Am J Manag Care. 2005;11(Spec No):SP7-13.
101. Murawski MM, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. Am J Manag Care. 2005;11(Spec No):SP35-42.
102. Ridley DB, Axelsen KJ. Impact of Medicaid preferred drug lists on therapeutic adherence. Pharmacoeconomics. 2006;24(Suppl 3):65-78.
103. Streja DA, Hui RL, Streja E, McCombs JS. Selective contracting and patient outcomes: a case study of formulary restrictions for selective serotonin reuptake inhibitor antidepressants. Am J Manag Care. 1999;5(9):1133-42.
104. Wilson J, Axelsen K, Tang S. Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. Am J Manag Care. 2005;11(Spec No):SP27-34.
105. Miller DP, Furberg CD, Small RH, et al. Controlling prescription drug expenditures: a report of success. Am J Manag Care. 2007;13(8):473-80.
106. Dunn JD, Cannon HE. Effects of a polypharmacy edit and reduced quantity limits on the utilization of triptans and overall costs in an integrated health system. Manag Care Interface. 2006;19(5):46-51.
107. Hoffman L, Mayzell G, Pedan A, Farrell M, Gilbert T. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. J Manag Care Pharm. 2003;9(4):335-45. Available at: http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=6831.